Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 23;5(1):e000254.
doi: 10.1136/lupus-2017-000254. eCollection 2018.

Kynurenine pathway is altered in patients with SLE and associated with severe fatigue

Karolina Åkesson #  1 , Susanne Pettersson #  2   3 , Sara Ståhl  4 , Izabella Surowiec  5 , Mattias Hedenström  5 , Susanna Eketjäll  6 , Johan Trygg  5 , Per-Johan Jakobsson  1 , Iva Gunnarsson  1 , Elisabet Svenungsson  1 , Helena Idborg  1
Affiliations

Kynurenine pathway is altered in patients with SLE and associated with severe fatigue

Karolina Åkesson et al. Lupus Sci Med. .

Erratum in

Abstract

Objective: Fatigue has been reported as the most disturbing symptom in a majority of patients with SLE. Depression is common and often severe. Together these symptoms cause significant morbidity and affect patients with otherwise relatively mild disease. Tryptophan and its metabolites in the kynurenine pathway are known to be important in several psychiatric conditions, for example, depression, which are often also associated with fatigue. We therefore investigated the kynurenine pathway in patients with SLE and controls.

Methods: In a cross-sectional design plasma samples from 132 well-characterised patients with SLE and 30 age-matched and gender-matched population-based controls were analysed by liquid chromatography tandem mass spectrometry to measure the levels of tryptophan and its metabolites kynurenine and quinolinic acid. Fatigue was measured with Fatigue Severity Scale and depression with Hospital Anxiety and Depression Scale. SLE disease activity was assessed with Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).

Results: The kynurenine/tryptophan ratio, as a measure of indoleamine 2,3-dioxygenase (IDO) activity, was increased in patients with SLE. Patients with active disease (SLEDAI ≥6) showed lower tryptophan levels compared with controls (54 µM, SD=19 vs 62 µM, SD=14, p=0.03), although patients with SLE overall did not differ compared with controls. Patients with SLE had higher levels of tryptophan metabolites kynurenine (966 nM, SD=530) and quinolinic acid (546 nM, SD=480) compared with controls (kynurenine: 712 nM, SD=230, p=0.0001; quinolinic acid: 380 nM, SD=150, p=0.001). Kynurenine, quinolinic acid and the kynurenine/tryptophan ratio correlated weakly with severe fatigue (rs =0.34, rs =0.28 and rs =0.24, respectively) but not with depression.

Conclusions: Metabolites in the kynurenine pathway are altered in patients with SLE compared with controls. Interestingly, fatigue correlated weakly with measures of enhanced tryptophan metabolism, while depression did not. Drugs targeting enzymes in the kynurenine pathway, for example, IDO inhibitors or niacin (B12) supplementation, which suppresses IDO activity, merit further investigation as treatments in SLE.

Keywords: autoimmune diseases; autoimmunity; disease activity; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SE is employed by AstraZeneca.

Figures

Figure 1
Figure 1
The kynurenic pathway. The encircled metabolites were measured and symbols indicate method and biological sample, that is, LC-MS/MS detection in plasma, NMR detection in urine and GC-MS detection in plasma. Our results comparing SLE and controls are represented by a hyphen if no change in metabolite level and an upward pointing arrow if the metabolite level was increased in SLE. Our hypothesis for a possible role of the kynurenic pathway in the pathogenesis of SLE is illustrated by dashed arrows. LC-MS/MS, liquid chromatography tandem mass spectrometry; GC-MS, gas chromatography mass spectrometry; NMR, nuclear magnetic resonance (NMR); ROS, reactive oxygen species; TNF-α, tumour necrosis factor alpha; mTOR, mammalian target of rapamycin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Meszaros ZS, Perl A, Faraone SV. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry 2012;73:993 doi:10.4088/JCP.11r07425 - DOI - PMC - PubMed
    1. Pettersson S, Lövgren M, Eriksson LE, et al. . An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life. Scand J Rheumatol 2012;41:383–90. doi:10.3109/03009742.2012.677857 - DOI - PubMed
    1. Beckerman NL. Living with lupus: a qualitative report. Soc Work Health Care 2011;50:330–43. doi:10.1080/00981389.2011.554302 - DOI - PubMed
    1. Fonseca R, Bernardes M, Terroso G, et al. . Silent burdens in disease: fatigue and depression in SLE. Autoimmune Dis 2014;2014:1–9. doi:10.1155/2014/790724 - DOI - PMC - PubMed
    1. Pettersson S, Möller S, Svenungsson E, et al. . Women’s experience of SLE-related fatigue: a focus group interview study. Rheumatology 2010;49:1935–42. doi:10.1093/rheumatology/keq174 - DOI - PubMed

LinkOut - more resources